Holen Sie sich die Stockscreener-App
1.58
0.00%
0.00
Handel nachbörslich:
1.65
0.07
+4.43%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.58
24-Stunden-Volumen:
612.99K
Relative Volume:
0.58
Marktkapitalisierung:
$108.02M
Einnahmen:
$593.00K
Nettoeinkommen (Verlust:
$-45.85M
KGV:
-2.3015
EPS:
-0.6865
Netto-Cashflow:
$-37.97M
1W Leistung:
+1.94%
1M Leistung:
-15.96%
6M Leistung:
-28.18%
1J Leistung:
-42.55%
1-Tages-Spanne:
$1.58
$1.64
1-Wochen-Bereich:
$1.545
$1.715
52-Wochen-Spanne:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.58 | 108.02M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Eingeleitet | Noble Capital Markets | Outperform |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
CRDF Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review - TipRanks
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cardiff Oncology director Dr. Erlander resigns - TradingView
Cardiff Oncology (CRDF) CEO awarded 600,000 options at $1.62 strike - stocktitan.net
[8-K] Cardiff Oncology, Inc. Reports Material Event - stocktitan.net
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Can Cardiff Oncology Inc reach all time highs this yearTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Noble Financial Issues Optimistic Estimate for CRDF Earnings - marketbeat.com
Growth Review: What is the PEG ratio of Cardiff Oncology Inc2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - stocktitan.net
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target By Investing.com - ca.investing.com
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com
William Blair reiterates Cardiff Oncology stock rating on drug data By Investing.com - ca.investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - MarketBeat
Cardiff Oncology Inc to Host KOL Webinar Transcript - gurufocus.com
Published on: 2026-03-26 02:49:36 - baoquankhu1.vn
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - ChartMill
Two cancer specialists join Cardiff talk on first-line colon cancer - stocktitan.net
Cardiff Oncology to present preclinical data at cancer conference By Investing.com - Investing.com Canada
Cardiff Oncology to present preclinical data at cancer conference - Investing.com
Cardiff Oncology Presents Promising Preclinical Data on Onvansertib at AACR Annual Meeting 2026 - Quiver Quantitative
Cardiff Oncology to Present Preclinical Data with Highly - GlobeNewswire
Levels Update: Can Cardiff Oncology Inc reach all time highs this year - baoquankhu1.vn
Ladenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy Recommendation - MSN
IPO Launch: Whats the analyst consensus on Cardiff Oncology IncWeekly Trade Review & High Conviction Trade Alerts - baoquankhu1.vn
Jobs Data: Is Cardiff Oncology Inc undervalued by DCF analysisWeekly Investment Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Rate Cut: Can Cardiff Oncology Inc reach all time highs this yearPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cardiff Oncology (STU:XE7C) NonCurrent Deferred Revenue : €0.00 Mil (As of Dec. 2025) - GuruFocus
What is Zacks Research’s Forecast for CRDF FY2027 Earnings? - Defense World
What is Zacks Research's Forecast for CRDF FY2027 Earnings? - MarketBeat
CRDF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat
Cardiff Oncology, Inc. (CRDF) - Minichart
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
CRDF: 10-K Filing Prompts Model Update - Yahoo Finance
HC Wainwright Issues Optimistic Outlook for CRDF Earnings - MarketBeat
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC - Defense World
CRDF: Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials - TradingView
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
CRDF: Today's Analyst Ratings and Price Target Adjustment | CRDF Stock News - GuruFocus
Cardiff Oncology advances onvansertib program in colorectal cancer - TipRanks
3 ‘Strong Buy’ Stocks to Buy Today, 2/25/2026, According to Top Analysts - TipRanks
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):